The Japanese pharmaceutical market ranks second following the U.S. in terms of pharmaceutical market size, and is together with Australia one of the two most mature markets within the Asia Pacific region. In addition, the new guideline released by Japan’s Pharmaceutical and Medical Devices Agency on “Basic Concept for International Joint Clinical Trials” in September 2007 has set a major milestone for the clinical trial environment in Japan. The new guideline opens up new opportunities for Japanese and global biopharmaceutical companies. By having flexibility in the acceptance of foreign data of ethnic similarity, Japanese companies have the opportunity to expedite development programs as well as expand their products into new markets. Meanwhile, global biopharmaceutical companies are encouraged to include Japan in their early development of a clinical trial.
Key advantages in Japan that could benefit your clinical trial are:
PAREXEL’s strong presence and expertise in the region can assist you in developing your full phase clinical trial programs and penetrate into new markets. Our team of dedicated experts are readily available to cater to your needs and queries. Click here to view Japan locations.
